![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The proceeds from the financing will be used to advance Augustine’s lead candidate, AGT100216, into early-stage clinical trials for the treatment of CMT and CIPN.
Lead Product(s): AGT100216
Therapeutic Area: Neurology Product Name: AGT100216
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $18.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 26, 2024